Accelerating research

and development of

new antibiotics and

alternatives

The Netherlands Antibiotic Development Platform

The Netherlands Antibiotic Development Platform (NADP) facilitates the collaboration between public and private organisations, to enhance the development of new antibiotics and alternative therapies for infectious diseases in humans and animals.

NADP will identify relevant research groups, institutes and companies involved in chemical, biological, and/or biomedical antibiotic research to forge collaborations through targeted connections and will organise regular meetings with interested parties. At a later stage, the NADP will provide Drug Discovery Management support/vouchers and Intellectual Property and Technology Transfer Office support.

News

Science and industry work together on affordable alternatives to antibiotics

19 December 2017

Almost fifty scientists and twenty companies will work on the development of new antibiotics and alternatives to antibiotics, which must become available for the healthcare system for a fair and affordable price. The research is done in eight projects that have received the green light from NWO Domain Applied and Engineering Sciences (AES). Together with the Ministry of Health, Welfare and Sport (VWS), NWO invests almost 7 million euros in the research programme.

Read more

Company in the spotlight: AGILeBiotics B.V.

14 December 2017

NADP supports R&D collaborations. To give further insights in companies active in this area, we have initiated the column“Company in the spotlight” issue. In this first edition, we speak with Dr. Andreas Bastian, the CEO of AGILeBiotics B.V. This antimicrobial developing company was founded earlier this year and is a perfect candidate to kick-off this topic!

Read more

Events

Symposium on the Clinical Utility of Bacteriaphages

The 11th Berlin Conference on Life Sciences – Novel Antimicrobials and AMR Diagnostics

28th ECCMID 2018

Funding Opportunities

A list of funding opportunities, with topics around antimicrobial resistance, development of new antibiotics and alternative therapies.

NADP Partners

CARES-Logo-150x82
CeSAM-logo-147x82
ImmunoValley-logo-210x82
NCOH-logo-210x82

Supported by

Ministerie-VWS